Scarica l'app Stockscreener
1.78
10.55%
-0.21
Dopo l'orario di chiusura:
1.82
0.04
+2.25%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GANX Giù?
Forum
Previsione
Precedente Chiudi:
$1.99
Aprire:
$1.99
Volume 24 ore:
608.85K
Relative Volume:
1.71
Capitalizzazione di mercato:
$48.53M
Reddito:
$210.70K
Utile/perdita netta:
$-22.22M
Rapporto P/E:
-0.978
EPS:
-1.82
Flusso di cassa netto:
$-17.13M
1 W Prestazione:
+14.84%
1M Prestazione:
+63.30%
6M Prestazione:
-52.79%
1 anno Prestazione:
-45.73%
Intervallo 1D:
$1.63
$1.99
Intervallo di 1 settimana:
$1.538
$2.00
Portata 52W:
$0.89
$5.33
Gain Therapeutics Inc Stock (GANX) Company Profile
Nome
Gain Therapeutics Inc
Settore
Industria
Telefono
(301) 500-1556
Indirizzo
4800 HAMPDEN LANE, BETHESDA
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-04-12 | Iniziato | BTIG Research | Buy |
| 2021-04-12 | Iniziato | Oppenheimer | Outperform |
Gain Therapeutics Inc Borsa (GANX) Ultime notizie
BTIG maintains Buy rating on Gain Therapeutics shares - Investing.com India
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers - The Manila Times
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s - The Bakersfield Californian
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers - StockTitan
Understanding the Risks of Investing in Gain Therapeutics Inc (GANX) - Knox Daily
Nuvation Bio Inc [NUVB] Investment Appeal on the Rise - Knox Daily
Gain Therapeutics Inc [NASDAQ: GANX] Sees Increase in Stock Value - Knox Daily
Gain Therapeutics Inc (GANX) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease - The Manila Times
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming - The Bakersfield Californian
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease - StockTitan
Can you still get a good price for Perspective Therapeutics Inc (CATX) Shares at this point? - US Post News
Can you still get a good price for Black Diamond Therapeutics Inc (BDTX) Shares at this point? - US Post News
Gaining Ground: BioXcel Therapeutics Inc (BTAI) Closes Lower at 0.58, Down -12.13 - The Dwinnex
Retail investors who hold 56% of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) gained 13%, institutions profited as well - Simply Wall St
Investors in Sangamo Therapeutics (NASDAQ:SGMO) from three years ago are still down 90%, even after 13% gain this past week - Yahoo Finance
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024 - StockTitan
Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year? - Yahoo Finance
Applied Therapeutics, PowerFleet, VF Corp, Victoria's Secret And Other Big Stocks Moving Higher On Wednesday - Benzinga
Investing in Sarepta Therapeutics (NASDAQ:SRPT) five years ago would have delivered you a 55% gain - Simply Wall St
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Gaining Ground: CytomX Therapeutics Inc (CTMX) Closes Lower at 1.23, Down -1.60 - The Dwinnex
Daily Market Movement: Spyre Therapeutics Inc. (SYRE) Sees a 3.23 Increase, Closing at 29.36 - The Dwinnex
Retail investors who hold 48% of Candel Therapeutics, Inc. (NASDAQ:CADL) gained 14%, insiders profited as well - Simply Wall St
Viking Therapeutics, Inc. (VKTX) Laps the Stock Market: Here's Why - MSN
Gain Therapeutics Inc (GANX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Solventum Shares May Gain on the Launch of Its New V.A.C Therapy - Yahoo Finance
Gain Therapeutics Inc (GANX) may enjoy gains as insiders got busy in the recent days - Knox Daily
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
Daily Market Movement: Apogee Therapeutics Inc. (APGE) Sees a 0.55 Increase, Closing at 47.51 - The Dwinnex
Viking Therapeutics, Inc. (VKTX) Laps the Stock Market: Here's Why - Yahoo Finance
Crude Oil Gains Over 1%; Relay Therapeutics Shares Spike Higher - Benzinga
Gaining Ground: Regulus Therapeutics Inc (RGLS) Closes Lower at 1.46, Down -6.41 - The Dwinnex
Market Watch: Verve Therapeutics Inc (VERV)’s Noteworthy Gain, Closing at 5.59 - The Dwinnex
Gain Therapeutics Initiates $50 million equity distribution - Investing.com
Cullinan Therapeutics Inc (CGEM) stock analysis: A comprehensive overview - US Post News
Gain Therapeutics’ (GANX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
BTIG maintains Buy rating on Gain Therapeutics shares By Investing.com - Investing.com Canada
Gain Therapeutics shares hold steady price target and Buy rating on clinical trial - Investing.com Canada
What is the investor’s view on Nurix Therapeutics Inc (NRIX)? - US Post News
Gain Therapeutics shares hold steady price target and Buy rating on clinical trial - Investing.com UK
It would be worthwhile to take a closer look at Gain Therapeutics Inc (GANX) - US Post News
Gain readies for Phase 1b trial of Parkinson’s therapy GT-02287 - Parkinson's News Today
Gaining Ground: Sangamo Therapeutics Inc (SGMO) Closes Higher at 0.85, Up 2.78 - The Dwinnex
Recent Insider Activity Could Benefit Gain Therapeutics Inc (GANX) - Knox Daily
Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Can you still get a good price for Aptevo Therapeutics Inc (APVO) Shares at this point? - US Post News
Daily Market Movement: Dermata Therapeutics Inc (DRMA) Sees a 1.16 Increase, Closing at 1.74 - The Dwinnex
Can you now get a good deal on Carisma Therapeutics Inc’s shares? - US Post News
Digital Therapeutics and Wellness Market is Projected to Increase at a Strong CAGR of 14.6% by 2033 | Future Market Insights, Inc. – Market Research Blog - Market Research Blog
Gain Therapeutics Inc Azioni (GANX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
4.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):